Lamin A/C truncation in dilated cardiomyopathy with conduction disease

Abstract

Background

Mutations in the gene encoding the nuclear membrane protein lamin A/C have been associated with at least 7 distinct diseases including autosomal dominant dilated cardiomyopathy with conduction system disease, autosomal dominant and recessive Emery Dreifuss Muscular Dystrophy, limb girdle muscular dystrophy type 1B, autosomal recessive type 2 Charcot Marie Tooth, mandibuloacral dysplasia, familial partial lipodystrophy and Hutchinson-Gilford progeria.

Methods

We used mutation detection to evaluate the lamin A/C gene in a 45 year-old woman with familial dilated cardiomyopathy and conduction system disease whose family has been well characterized for this phenotype [1].

Results

DNA from the proband was analyzed, and a novel 2 base-pair deletion c.908_909delCT in LMNA was identified.

Conclusions

Mutations in the gene encoding lamin A/C can lead to significant cardiac conduction system disease that can be successfully treated with pacemakers and/or defibrillators. Genetic screening can help assess risk for arrhythmia and need for device implantation.

Background

Dilated cardiomyopathy (DCM) is a disorder characterized by four-chamber dilation of the heart. DCM is often progressive and results in reduced heart function and congestive heart failure. Although etiologically diverse, inheritance is a significant contributor to the development of DCM. Supporting this, mutations in a number of different genes have recently been associated with familial forms of DCM [2], and mutations in the gene encoding lamin A/C appear to be a significant component. Lamins A and C are two different proteins produced by alternative splicing from the same gene. They are identical along their first 566 amino acids and differ only in their carboxyl terminus. As specialized proteins of the intermediate filament protein family, lamin A/C is found at the inner nuclear membrane where it forms a scaffold that interacts with a network of membrane bound and nucleoplasmic proteins in addition to chromatin [3–5]. Mutations in the gene encoding the nuclear membrane protein emerin produce autosomal recessive Emery Dreifuss Muscular Dystrophy, a disorder that phenotypically overlaps the neuromuscular and cardiovascular features seen with lamin A/C mutations [6]. Consistent with this, lamin A/C directly binds emerin [7, 8]. Lamins A and C are broadly expressed in many different cell types and are primarily expressed in terminally differentiated cells. It is not known how mutations in LMNA lead to tissue-specific phenotypes.

The first autosomal dominant form of cardiomyopathy was mapped in 1994 to the centromeric region of chromosome 1 [9]. Linkage was achieved using genetic and clinical material from a large, well-characterized kindred [1]. One of the striking characteristics from this family was the degree of cardiac conduction system disease that primarily targeted the atrioventricular node [1, 10]. Many members of the kindred exhibited sick sinus syndrome, atrial fibrillation and sudden death.

In addition to DCM with conduction system disease and variable skeletal muscle involvement, mutations in the Lamin A/C gene [OMIM 150330] have been shown to cause autosomal dominant [11] and autosomal recessive [12] Emery-Dreifuss Muscular Dystrophy (EDMD), autosomal dominant limb-girdle muscular dystrophy type 1B (LGMD) [13], autosomal recessive type 2 Charcot-Marie Tooth type 2 [14], familial partial lipodystrophy [15, 16], Mandibuloacral dysplasia [17] and Hutchinson-Gilford progeria [18]. The phenotypic spectrum from DCM to EDMD and limb girdle muscular dystrophy appears continuous. However, the mechanism by which LMNA mutations lead to cardiac versus skeletal muscle disease is unknown.

We now evaluated a woman with DCM and sinus bradycardia. Her immediate family history was significant for symptomatic bradycardia requiring pacemaker implantation. She is a member of the kindred initially described by Graber et al [1]. We screened this individual for mutations and found a novel mutation in exon 5 of LMNA. This two bp deletion is predicted to disrupt the reading frame and produce a truncated lamin A and C.

Methods

Patient recruitment

Written and informed consent was obtained in accordance with the University of Chicago's Institutional Review Board. Clinical data were obtained through evaluations performed at the University of Chicago.

Genetic Analysis

DNA extraction from blood was performed using PureGene according to the manufacturer's recommendations. PCR primers were designed to amplify all twelve protein coding exons of LMNA (Table I). DHPLC analysis of each exon was carried out on a WAVE™ (Transgenomic); exon 5 was analyzed at 65.2°C with 51%-56%-65% acetonitrile. SSCP was performed using MDE™ (FMC) as described [19]. Direct sequencing of PCR products was completed using cycle sequencing. To confirm the presence of the mutation, PCR products were purified and digested with AlwN I.

Table 1 Primers for amplifying LMNA for DHPLC and SSCP analysis. All sequences are listed 5' to 3'.

Results

Phenotype Analysis

A 45 year-old Caucasian woman with a history of paroxysmal atrial fibrillation, sick sinus syndrome, dilated cardiomyopathy, and fatigue was seen in the University of Chicago's Cardiovascular Genetics Clinic for evaluation and treatment. The patient is a member of a large kindred previously described [1, 9, 10]. The patient was evaluated by EKG (Figure 1) that demonstrated marked sinus bradycardia and first degree atrioventricular block. An echocardiogram showed moderate dilation of the left ventricle (5.3 cm end diastolic internal diameter) and mild dilation of the right ventricle. The left ventricular performance was estimated as the lower end of normal with a normal fractional shortening (42%) (Figure 2). The patient reported no neuromuscular complaints, and on physical exam showed no overt muscle weakness.

Figure 1

EKG Shown is the 12 lead electrocardiogram performed prior to pacemaker-defibrillator implantation. Each box represents 200 msec. Sinus bradycardia is present; the proband's baseline heart rate was 45 beats per minute (normal is 80 beats per minute). First degree atrioventricular heart block is present (circled) as the conduction time between the atrial deflection and the ventricular deflection is 240 msec (normal is up to 200 msec).

Figure 2

Echo Shown is an M-mode echocardiogram through the diameter of the left ventricle revealing mild dilation. The left vertical line marks the dimension of the ventricle in diastole at its greatest, and this dimension is 5.3 cm (above the 95^th percentile for body mass index). The fractional shortening was normal and the ejection fraction was read as low normal consistent with the mildly dilated left ventricle.

The pedigree for this proband is shown in Figure 3. All affected individuals had undergone pacemaker implantation for symptomatic bradycardia. Her mother reported fatigue and was also noted to have an abnormal skeletal muscle biopsy. Because of her marked fatigue and family history of sudden death, a dual chamber pacemaker and automatic defibrillator were implanted. Of note, the proband reported an improvement in her fatigue symptoms after pacer implantation. With pacemaker implantation, her baseline heart rate improved from 40 bpm to 80 bpm.

Figure 3

Pedigree Shown is the pedigree ascertained from the proband (indicated with an asterisk). Affected individuals are shown in black. Each affected individual had undergone pacemaker implantation for bradycardia. Shown in gray are individuals with a history of heart disease or sudden death.

Genotype Analysis

All twelve exons of LMNA were screened by denaturing high performance liquid chromatography (DHPLC) and single strand conformation polymorphism (SSCP) (Figure 4). In exon 5, a two bp (CT) deletion was detected in the LMNA gene (Figure 5). The two bp deletion falls into positions 908 and 909 of the NCBI Accession # NM_170708 where 1 is the first coding nucleotide. This frameshift mutation is expected to disrupt the lamin A and C sequences after the first 302 amino acids. In addition, 26 novel amino acids (CPAQPAPEAAGSQGGEASRPGGLTGP) are added after the truncation. The relatively high proline content of this additional sequence and the positioning of this truncation would be expected to disrupt the second half of the coiled-coil region of the protein. An additional 98 unrelated subjects with dilated cardiomyopathy were screened by SSCP and DHPLC and found not to carry the 908_909delCT mutation. Finally, 100 chromosomes from control DNA samples were checked and found not to carry the 908_909delCT mutation.

Figure 4

DHPLC A. DHPLC was used to detect an aberrant migration pattern (green) in the proband's DNA. The arrow indicates the polymorphism that correlates with the 2 bp deletion. B. Sequence analysis of LMNA exon 5 amplified directly from the proband's DNA revealed double-banding indicative of a frameshift mutation. To isolate the mutant allele, SSCP was used. Sequence of the mutant allele revealed a two bp deletion (top sequence). This deletion is predicted to truncate lamin A/C at amino acid 302 and add a novel 26 amino acids. The predicted protein product, if made, would be approximately 37 KDa and would disrupt the helical nature of lamin A/C and lack the carboxy-terminal globular region.

Figure 5

Digest with AlwN I to confirm the 908_909delCT mutation. The 908_909delCT mutation creates a novel AlwN I restriction site. Exon 5 was amplified from the proband and control genomic DNA and subsequently digested with AlwN I. Where control DNA lacks an AlwN I site (294 bp), the proband's exon 5 was digested with AlwN I generating fragments of 194 bp and 119 bp. DNA from 100 ethnically-matched control chromosomes was similarly checked for this mutation and did not have the 908_909delCT mutation. Lane 1, control; Lane 2, proband; Lane 3, size markers.

Discussion

Our findings demonstrate a novel mutation in lamin A/C in a proband whose family was previously linked to DCM with conduction disease and chromosome 1q21.2 locus [9]. Mutations in the LMNA gene associated with DCM have a more severe prognosis and higher-event rates compared to individuals with DCM that do not have LMNA mutations [20]. A recent report describing another family with a LMNA mutation causing DCM and conduction system disease documents the need for permanent pacemaker implantation [21]. Previous reports on the proband's kindred support a high-event rate in family members often resulting in sudden cardiac death even in family members with permanent pacemakers [10]. For example, ten out of 38 family members with pacemakers for high-grade atrioventricular block died suddenly. Subjects with LMNA mutations should be carefully evaluated for both pacemakers and defibrillators.

It is presently unknown whether autosomal dominant lamin A/C mutations impart their phenotype through dominant negative or haploinsufficient mechanisms. The majority of reported LMNA mutations are missense. In this case, the mutant protein is thought to be expressed and to act through a dominant interfering mechanism. A smaller number of LMNA mutations are frameshifting and are expected to create truncated lamin A and C. In at least one case, a nonsense mutation at amino acid position 6 was described [11]. This mutation is effectively a null allele and therefore, dominant mutations, at least in this case, would be expected to arise from haploinsufficiency of lamin A/C. Of note, mice with a null allele in lmna display a phenotype only in the homozygous state [22]. The mutation we now describe is predicted to generate a substantial protein fragment consisting of the first 37 KDa of lamin A/C. The novel, proline-rich sequence that is predicted at the carboxyl terminus of the truncated lamin A/C may further interfere with lamin function. Lamins assemble into a higher order structure and truncations may interfere with this assembly. The presence of aberrantly assembled lamin filaments may also interfere with other lamin-interacting proteins such as emerin or nesprin-1α [23].

The exact mechanism by which LMNA mutations cause disease is not clearly elucidated at this time. However, it is clear that mutations in LMNA cause tissue-specific disease affecting various differentiated cells including cardiac and skeletal muscle, adipocytes and neurons. This suggests that lamin's role at the nuclear membrane affects both cell-type and tissue-specific processes. Currently, there are at least two theories regarding the effects of LMNA [24]. The first postulates that disruptions of the inner nuclear membrane affect heterochromatin scaffolding and thereby gene expression. In this model, lamin A/C is necessary for the appropriate expression of tissue-specific genes. The second theory, the mechanical stress hypothesis, suggests weakness in the nuclear lamina leaves certain tissues more prone to damage by force. This model was first raised when LMNA mutations were primarily associated with disorders affecting striated muscle [24]. Interestingly, the preferential involvement of the specialized cells of the cardiac conduction system may support less the stress hypothesis as the cells of the atrioventricular node are less expected to undergo considerable deformation. The additional phenotypes now associated with LMNA mutations also favor alternative mechanisms of pathogenicity.

Conduction disease preceded the development of dilated cardiomyopathy in the proband's family [1, 10]. This indicates the necessity for careful documentation of a three-generation pedigree in the evaluation of patients with conduction system disease paying particular attention to sudden death, arrhythmia and bradycardia. Genotyping of patients with conduction disease and DCM may provide important information regarding device implantation. Genetic counseling for patients and family members should always accompany genetic testing as variable expressivity and age dependent penetrance may influence clinical decision making [25].

Conclusions

Individuals with DCM and conduction system disease should be screened by family history and genetic testing. Those found to have mutations in lamin A/C should be evaluated for placement of pacemakers and automatic defibrillators in order to prevent the sudden cardiac death associated with this disease.

Authors Contributions

HMM was responsible for gathering patient data. MRC and JMH carried out mutation detection. EMM conceived the study and evaluated the data. The manuscript was written and approved by all authors.